Recently, both the FDA [99] and the EMA [100] have produced a Drug Safety Communication on the risk of diabetic ketoacidosis (DKA) in diabetic patients treated with SGLT2 inhibitors. Here, SLC5A2 is linked to diabetic ketoacidosis.